Speranta IACOB medic specialist gastroenterolog, doctor in stiinte medicale Data si locul nasterii: 8 aprilie 1977, Bucuresti, Romania Telefon/Fax:

Size: px
Start display at page:

Download "Speranta IACOB medic specialist gastroenterolog, doctor in stiinte medicale Data si locul nasterii: 8 aprilie 1977, Bucuresti, Romania Telefon/Fax:"

Transcription

1 Speranta IACOB medic specialist gastroenterolog, doctor in stiinte medicale Data si locul nasterii: 8 aprilie 1977, Bucuresti, Romania Telefon/Fax: msiacob@yahoo.com Etape medicale si universitare: : UMF Carol Davila, Bucuresti, Facultatea de Medicină Generală Medic rezident pediatrie, Clinica de Pediatrie, Institutul Clinic Fundeni, Bucuresti Medic rezident gastroenterologie, Centrul de Gastroenterologie si Hepatologie, Institutul Clinic Fundeni, Bucuresti Octombrie Promovarea examenului de medic specialist în gastroenterologie; încadrarea ca medic specialist la Centrul de Gastroenterologie si Hepatologie Fundeni 2007 prezent Medic specialist gastroenterologie, Centrul de Gastroenterologie si Hepatologie, Institutul Clinic Fundeni, Bucuresti Martie Promovarea examenului de asistent de cercetare în gastroenterologie : Asistent de cercetare, Centrul de Gastroenterologie si Hepatologie, Institutul Clinic Fundeni, Bucuresti Septembrie Promovarea examenului de cercetător stiintific în gastroenterologie : Cercetator stiintific, Centrul de Gastroenterologie si Hepatologie, Institutul Clinic Fundeni, Bucuresti Noiembrie 2010 Promovarea examenului pentru ocuparea postului de medic specialist gastroenterologie : Doctorand in specialitatea Chirugie Generala Transplant hepatic Conducator stiintific Prof. Dr. Irinel Popescu 12 Noiembrie 2010 Sustinerea tezei de doctorat cu titlul Hepatita cronica C recurenta posttransplant hepatic strategii terapeutice si factori asociati recurentei severe si obtinerea titlului de Doctor in stiinte medicale

2 7 Septembrie 2011 Promovarea examenului organizat de UEMS (European Union of Medical Specialists), EBTM (European Board of Transplantation Medicine) si ESOT (European Society of Organ Transplantation) si obtinerea Diplomei Europene in Medicina de Transplant ( European Diploma in Transplantation Medicine ) Pregatire postuniversitara in gastroenterologie si hepatologie Curs si stagiu practic de gastroenterologie si hepatologie Franta : EDOUARD HERRIOT hopital, Lyon (March April 2002) Curs si stagiu practic de gastroenterologie si hepatologie Olanda : Amsterdam (Academic Medical Center), Zwolle (The Sophia Ziekenhuis Zwolle) (Septembrie Octombrie 2003) 25 cursuri postuniversitare ( ) EASL School of Hepatology Curs 1 Bolile cronice hepatice, Geneva, Elvetia (Decembrie 2003) EASL School of Hepatology Curs 2 Complicatiile cirozei si cancerul hepatic, Barcelona, Spania (Iunie 2004) DAAD Scholarship SUPRASPECIALIZARE TRANSPLANT HEPATIC, Spitalul Universitar Essen, Germania (1 Iunie 30 Noiembrie 2005) Stagiu de cercetare fundamentala in Biologie Moleculara si Celulara, Spitalul Universitar Essen, Germania (1 Ianuarie 31 Decembrie 2009) Afiliere la societati: AN SOCIETATE 2001-prezent Membra a Societatii Romane de Gastroenterologie si Hepatologie (SRGH) 2001-prezent Membra a Societatii Romane de Endoscopie Digestiva (SRED) 2002-prezent Membra a Societatii Romane de Nutritie Enterala si Parenterala (ROSPEN) 2002-prezent Membra a ROMTRANSPLANT 2003-prezent Membra a International Association of Surgeons and Gastroenterologists (IASG) 2003-prezent Membra a American College of Gastroenterology (AGA) Feb prezent Membra a European Association for the Study of the Liver (EASL) Iunie 2008-prezent Membra a Transplantation Society (TTS) August 2008-prezent Membra a European Society for Organ Transplantation (ESOT) Septembrie 2008 Includere in WHO s WHO in lume in 2009 Iulie 2009 prezent Membra fondatoare a Women Leaders in Transplantation (WLIT) Premii si burse primite: - 19 burse ca tanar investigator pentru participare la diferite congrese internationale (incepand din ) - Bursa acordata de DAAD (Serviciul German de Schimb Academic) (2005) - Bursa de cercetare acordata pentru tinerii doctoranzi de catre CNCSIS (Mai 2007-Martie 2010) - Invitata de catre Societatea Internationala de Transplant la TTS New KOL Meeting as New Key Opinion Leader (nkol), Sankt Petersburg, Russia Real time elastography a noninvasive tool for evaluation of recurrent hepatitis C following liver transplantation premii (premiul I, II, III si mentiune) pentru prezentari orale sau postere (4

3 premii internationale si 11 premii nationale) Arii de interes in cercetare Transplantul hepatic Diagnosticul si tratamentul hepatitelor virale Ciroza hepatica si managementul complicatiilor Bolile colestatice ale adultului Boala Wilson hepatica Cancerul hepato-biliar diagnostic precoce si tratament Participare la granturi obtinute prin concurs: : 3 granturi nationale (unul de aproximativ 26000Eur, 2 de ~19000Eur) : 4 granturi nationale (fiecare de Eur) : 3 granturi nationale (fiecare de ~ Eur) Participare la 7 trialuri medicale internationale (co-investigator) Lucrari elaborate: Lucrari originale publicate in extenso 1. Diculescu M., Iacob S., Iacob R., Sclifos D., Ionescu R., Oproiu A. - Is oral bile acid dissolution a better alternative to laparoscopic cholecystectomy for patients with gallbladder stones? - Annals of Fundeni Hospital vol 6, nr. 1, january-march 2001, pp Diculescu M., Iacob R, Iacob S., Croitoru A., Becheanu G., Popeneciu V. - The Importance of Histopathological and Clinical Variables in Predicting the Evolution of Colon Cancer - Romanian Journal of Gastroenterology 2002 Sep;11(3): Gheorghe C., Gheorghe L., Iacob R., Iacob S., Simionov I., Bancila I. Argon Plasma Coagulation for Radiation Proctitis Romanian Journal of Gastroenterology 2003 June; 12(2): Vadan R., Gheorghe L., Becheanu G., Iacob R., Iacob S., Gheorghe C. Predictive factors for the severity of liver fibrosis in patients with chronic hepatitis C and moderate alcohol consumption - Romanian Journal of Gastroenterology 2003 Sep; 12(3): Gheorghe L, Iacob S, Bolog N, Stoicescu A, Parvulescu I, Popescu I. Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis complicated by hepatocellular carcinoma. Case report - Romanian Journal of Gastroenterology 2004 March; 13 (1): Gheorghe L, Iacob S, Gheorghe C, Iacob R, Simionov I, Vadan R, Becheanu G, Parvulescu I, Toader C. - Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease European Journal of Gastroenterology and Hepatology 2004; June, 16 (6): Gheorghe L., Popescu I., Iacob S., Gheorghe C., Vadan R., Constantinescu A., Iacob R., Becheanu G., Angelescu C, Diculescu M. - Wilson s disease: a challenge of diagnosis. The 5-years experience of a tertiary center - Romanian Journal of Gastroenterology 2004 September; 13 (3): C. Gheorghe, O. Pascu, L. Gheorghe, R. Iacob, E. Dumitru, M. Tantau, R. Vadan, A. Goldis, G. Balan, S. Iacob, D. Dobru, A. Saftoiu. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentric study - European Journal of Gastroenterology and Hepatology 2004; November, 16 (11): L. Gheorghe, S. Iacob, I. Popescu. Living donor liver transplantation and hepatitis C. Rom J Gastroenterol 2004 December; 13 (4):

4 10. Diculescu M, Iacob R, Chira C, Mihaila D, Iacob S. Esomeprazole in the treatment of patients with heartburn and other upper gastrointestinal symptoms, referred to primary care - results of the in-practice evaluation program in Romania. Rom J Gastroenterol Mar;14(1): Gheorghe L, Popescu I, Iacob R, Iacob S, Gheorghe C. Predictors of death on the waiting list for liver transplantation characterized by a long waiting time. Transpl Int May;18(5): Gheorghe L., Grigorescu M., Iacob S., Damian D., Gheorghe C., Iacob R., Simionov I., Vadan R., Parvulescu I., Bancila I. Effectiveness and tolerability of Pegylated interferon α-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice - Rom J Gastroenterol Jun;14(2): Gheorghe L, Iacob R, Vadan R, Iacob S, Gheorghe C. Improvement of hepatic encephalopathy using a modified high-calorie high-protein diet. Rom J Gastroenterol Sep;14(3): Gheorghe L, Iacob S, Simionov I, Vadan R, Gheorghe C, Iacob R, Parvulescu I, Constantinescu I. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol Dec;14(4): Iacob R, Iacob S, Gheorghe L, Gheorghe C, Diculescu M. The use of IT in the medical system has economic and research advantages - the experience of Fundeni Gastroenterology and Hepatology Center. Rom J Gastroenterol Dec;14(4): Cristian Gheorghe, Liana Gheorghe, Speranta Iacob, Razvan Iacob, Irinel Popescu. Primary prophylaxis of variceal bleeding in cirrhotics awaiting liver transplantation. Hepato-Gastroenterology 2006; 53: Popescu I, Tulbure D, Gheorghe L, Hrehoret D, Popa L, Iacob S, Malago M. Emergency protocol for an adult ABO-incompatible living related liver transplantation. Annals of Fundeni Hospital 2006;10: Gheorghe L, Iacob S, Sporea I, Grigorescu M, Sirli R, Damian D, Gheorghe C, Iacob R. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN α-2b and ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16(1): Speranta Iacob, Vito R. Cicinnati, Philip Hilgard, Razvan A. Iacob, Liana S. Gheorghe, Irinel Popescu, Andrea Frilling, Massimo Malago, Guido Gerken, Christoph E. Broelsch, Susanne Beckebaum. Predictors of graft and patient survival in HCV recipients - model to predict HCV cirrhosis following liver transplantation. Transplantation 2007; 84:56-63 *Models for predicting graft and patient survival and hepatitis C virus recurrence after liver transplantation Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Iacob S, Cicinnati VR, Hilgard P, Iacob RA, Gheorghe LS, Popescu I, et al. Transplantation 2007; 84:56-63 Comments by Perkins JD. In Liver Transplantation 2008;14: Cicinnati VR, Iacob S, Klein CG, Baba HA, Sotiropoulos GC, Hilgard P, Erim Y, Broelsch CE, Gerken G, Beckebaum S. Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2007; 26:

5 21. L. Gheorghe, S. Iacob, R. Iacob, C. Gheorghe, I. Popescu. Variation of the MELD score as a predictor of death on the waiting list for liver transplantation. J Gastrointestin Liver Dis 2007; 16(3): *Lake JR. MELD-an imperfect, but thus far the best, solution to the problem of organ allocation. J Gastrointestin Liver Dis 2008; 17 (1): Gheorghe L, Iacob S, Gheorghe C, Herlea V, Becheanu G, Ardeleanu C, Dumbrava M, Lupescu I, Popescu I. Ecoendoscopic elastography for the diagnosis of hepatocellular carcinoma in small cirrhotic nodules. Archives of the Balkan Medical Union 2007; 42: Popescu I, Dima S, Guja C, Gheorghe L, Iacob S, Hrehoret D, Matei E, Dorobantu B, Botea F, Sarbu V, Tulbure D, Ionescu-Tirgoviste C. Combined liver and islet transplantation using steroid-free immunossupression. Chirurgia (Bucur) 2007;102: Gheorghe L, Iacob S, Lupescu I, Popescu H, Budai A. Percutaneous radiofrequency ablation for hepatocellular carcinoma. Archives of the Balkan Medical Union 2008; 43: Speranta Iacob, Liana Gheorghe, Doina Hrehoret, Gabriel Becheanu, Vlad Herlea, Irinel Popescu. Pegylated Interferon α-2a and Ribavirin Combination Therapy in HCV Liver Transplant Recipients. Experience of 7 Cases. J Gastrointestin Liver Dis 2008; 17: Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania: Different from European rates? J Hepatol 2008; 49(4): Gheorghe C, Iacob R, Gheorghe L, Cotruta B, Bancila I, Iacob S, Bucur D, Voinea D, Popescu I. Projected Dynamics of Colonoscopic Screening and Surveillance for Colorectal Cancer. Hepato-Gastroenterology 2008; 55: Gheorghe L, Iacob S, Gheorghe C. Real-time sonoelastography a new application in the field of liver disease. J Gastrointestin Liver Dis. 2008;17(4): Iacob S, Hrehoret D, Matei E, Dorobantu B, Gangone E, Gheorghe L, Popescu I. Costs and efficacy of "on demand" low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis. 2008;17(4): Gheorghe L, Iacob S, Grigorescu M, Sporea I, Sirli R, Damian D, Gheorghe C, Iacob R. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C. J Gastrointestin Liver Dis 2009;18: Iacob R, Sirbu-Boeti P, Iacob S, Dima S, Gheorghe C, Gheorghe L; Popescu I. Stem cell therapies for gastrointestinal and liver diseases. Chirurgia (Bucur) 2009;104: Iacob S, Gheorghe L, Iacob R, Gheorghe C, Hrehoret D, Popescu I. MELD exceptions and new predictive score of death on long waiting lists for liver transplantation. Chirurgia (Bucur) 2009;104: Popescu I, Habib N, Dima S, Hancu N, Gheorghe L, Iacob S, Mihaila M, Dorobantu B, Matei E, Botea F. Domino liver transplantation using a graft from a donor with familial hypercholesterolemia: seven-yr follow-up. Clinical Transplant 2009;23: Gheorghe L, Iacob S, Iacob R, Dumbrava M, Becheanu G, Herlea V, Gheorghe C, Lupescu I, Popescu I. Real Time Elastography a noninvasive diagnostic method of small hepatocellular carcinoma in cirrhosis. J Gastrointestin Liver Dis 2009;18 (4):

6 35. Dima S, Iacob S, Botea F, Matei E, Brasoveanu V, Hrehoret D, Vasile S, Alexandrescu S, Croitoru A, Dumitrascu T, Herlea V, Popescu I. Multimodal Treatment of Hepatocellular carcinoma: An Eastern European Experience. Hepato-Gastroenterology 2009; 56 (96): Iacob S, Cicinnati VR, Beckebaum S. Current immunosuppressive approaches in liver transplantation. Panminerva Med 2009;51: Beckebaum S, Iacob S, Klein CG, Dechêne A, Varghese J, Baba HA, Sotiropoulos GC, Paul A, Gerken G, Cicinnati VR. Assessment of Allograft Fibrosis by Transient Elastography and Noninvasive Biomarker Scoring Systems in Liver Transplant Patients. Transplantation. 2010;89: Popescu I, Ionescu M, Brasoveanu V, Hrehoret D, Matei E, Dorobantu B, Zamfir R, Alexandrescu S, Grigorie M, Tulbure D, Popa L, Ungureanu M, Tomescu D, Droc G, Popescu H, Cristea A, Gheorghe L, Iacob S, Gheorghe C, Boros M, Lupescu I, Vlad L, Herlea V, Croitoru M, Platon P, Alloub A. Liver transplantation - indications, surgical technique, results - the analysis of a clinical series of 200 cases. Chirurgia 2010;105: Gheorghe L, Pascu O, Ceausu E, Csiki IE, Iacob S, Caruntu F, Simionov I, Vadan R. Access to Peginterferon plus Ribavirin therapy for hepatitis C in Romania between J Gastrointestin Liver Dis 2010; 19: Shen Q, Cicinnati V, Zhang X, Iacob S, Weber F, Sotiropoulos G, Radtke A, Lu M, Paul A, Gerken G, Beckebaum S. Role of microrna-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Molecular Cancer 2010, 9: Sporea I, Sirli R, Curescu M, Gheorghe L, Popescu A, Bota S, Iacob S. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients. J Gastrointestin Liver Dis. 2010;19(3): Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey J Gastrointestin Liver Dis. 2010;19(4): Beckebaum S, Iacob S, Sweid D, Sotiropoulos GC, Saner F, Kaiser G, Radtke A, Klein CG, Erim Y, de Geest S, Paul A, Gerken G, Cicinnati VR. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int 2011 [Ebup ahead of print] Capitole de carte: 17 Articole tip review: 6 Lucrări publicate în rezumat la manifestări stiintifice internationale si nationale:210 Comunicari orale: 19 internationale, 30 nationale, 25 regionale Postere prezentate la manifestări stiintifice internationale si nationale: 223 Publicatii cu caracter educational: 9

In prezent: Cercetator stiintiific grad III, medic primar gastroenterologie Centrul de Gastroenterologie si Hepatologie Institutul Clinic Fundeni

In prezent: Cercetator stiintiific grad III, medic primar gastroenterologie Centrul de Gastroenterologie si Hepatologie Institutul Clinic Fundeni CURRICULUM VITAE Nume: VĂDAN ROXANA Data naşterii: 3.05. 1970 Locul naşterii: Bucureşti Adresa (spital): Centrul de Gastroenterologie si Hepatologie, Institutul Clinic Fundeni; Soseaua Fundeni nr 258,

More information

CURRICULUM VITAE CRISTIAN GHEORGHE

CURRICULUM VITAE CRISTIAN GHEORGHE 1 CURRICULUM VITAE CRISTIAN GHEORGHE Profesor, medic primar medicină internă si gastroenterologie, doctor în medicină, şef secţia I Gastroenterologie, Centrul pentru Boli Digestive si Transplant Hepatic,

More information

4th UpDate on Hepatology

4th UpDate on Hepatology 4th UpDate on Hepatology Course Bucharest 2017, Romania 6 th - 7 th April 2017 Bucharest - Crowne Plaza Hotel Hepatology 2017 A panoramic view" Liana GHEORGHE Course Directors Ioan SPOREA Anca TRIFAN 4

More information

Dynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy

Dynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy Dynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy Liana Gheorghe 1, Speranta Iacob 1, Razvan Iacob 1, Gabriela Smira 1, Corina Pietrareanu 1, Doina

More information

Access to Peginterferon plus Ribavirin Therapy for Hepatitis C in Romania between

Access to Peginterferon plus Ribavirin Therapy for Hepatitis C in Romania between Access to Peginterferon plus Ribavirin Therapy for Hepatitis C in Romania between 2002-2009 Liana Gheorghe 1, Oliviu Pascu 2, Emanoil Ceausu 3, Irma Eva Csiki 4, Speranta Iacob 1, Florin Caruntu 5, Iulia

More information

LIVER TRANSPLANTATION SURVIVAL IN HEPATOCELLULAR CARCINOMA. FUNDENI CLINICAL INSTITUTE EXPERIENCE

LIVER TRANSPLANTATION SURVIVAL IN HEPATOCELLULAR CARCINOMA. FUNDENI CLINICAL INSTITUTE EXPERIENCE THE PUBLISHING HOUSE OF THE ROMANIAN ACADEMY MEDICINE Research article LIVER TRANSPLANTATION SURVIVAL IN HEPATOCELLULAR CARCINOMA. FUNDENI CLINICAL INSTITUTE EXPERIENCE Gabriela ȘMIRA¹, Vladislav BRASOVEANU²,

More information

Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection

Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat

More information

CURRICULUM VITAE. Vereanu Anca Delia. Adresa: Str. Erou Iancu Nicolae 67 B, Data nasterii : 31 iulie Nationalitatea : Romana

CURRICULUM VITAE. Vereanu Anca Delia. Adresa: Str. Erou Iancu Nicolae 67 B, Data nasterii : 31 iulie Nationalitatea : Romana CURRICULUM VITAE Vereanu Anca Delia Adresa: Str. Erou Iancu Nicolae 67 B, Vila 7, Voluntari, Ilfov Data nasterii : 31 iulie 1967 Nationalitatea : Romana Statut civil: Casatorita Telefon mobil: +40 722

More information

PROGRAMME AT A GLANCE

PROGRAMME AT A GLANCE PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver

More information

PRELIMINARY SCIENTIFIC PROGRAM :50 Meet the experts- Molecular mechanisms in IBD from basic science to therapy. Franco-Romanian Meeting

PRELIMINARY SCIENTIFIC PROGRAM :50 Meet the experts- Molecular mechanisms in IBD from basic science to therapy. Franco-Romanian Meeting PRELIMINARY SCIENTIFIC PROGRAM RCCC Annual Meeting 27th-29th of SEPEMBER 2018 Thursday 27 th of September 2018 7.30-8.00 Registration 8.00-9:50 Meet the experts- Molecular mechanisms in IBD from basic

More information

Liver transplantation and hepatitis C virus

Liver transplantation and hepatitis C virus Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

THE ROMANIAN HEPATITIS ACTION PAPER

THE ROMANIAN HEPATITIS ACTION PAPER 1 THE ROMANIAN HEPATITIS ACTION PAPER PRODUCED BY: EUROPEAN LIVER PATIENTS ASSOCIATION APAH-RO WRITTEN BY: ACHIM KAUTZ, POLICY DIRECTOR, ELPA CRISTINA ENESCU, REPRESENTATIVE, APAH-RO LILYANA CHAVDAROVA,

More information

NUME: Maria-Magdalena Gurzun

NUME: Maria-Magdalena Gurzun NUME: Maria-Magdalena Gurzun ADRESĂ: Spitalul Universitar de Urgență Militar Central, Strada Plevnei, nr 134, telefon: 021.319.30.56 Fax: 021.312.18. DATE PERSONALE: Locul și data nașterii: 15 iulie, 1982,

More information

SCIENTIFIC PROGRAM. The First Franco-Romanian Meeting

SCIENTIFIC PROGRAM. The First Franco-Romanian Meeting SCIENTIFIC PROGRAM RCCC Annual Meeting 27 th -29 th of September 2018 The First Franco-Romanian Meeting Thursday 27 th of September 2018 7.30-8.15 Registration 8.15-9:45 Meet the experts The therapeutic

More information

Life After SVR for Cirrhotic HCV

Life After SVR for Cirrhotic HCV Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data

More information

Learning Objectives. After attending this presentation, participants will be able to:

Learning Objectives. After attending this presentation, participants will be able to: Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation

More information

P R O G R A M. 08:50 09:10 Present and future of surgery of pancreatic cancer: how far can we go?

P R O G R A M. 08:50 09:10 Present and future of surgery of pancreatic cancer: how far can we go? P R O G R A M Course Day 1, Friday November 2, 2018 08:30 08:00 Official Opening Welcome Address 08:30 08:35 08:35 08:40 08:40 08:45 08:45 08:50 Jakob Izbicki (Germany), EFISDS President T. Seufferlein

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice 3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,

More information

POST TRANSPLANT OUTCOMES IN PSC

POST TRANSPLANT OUTCOMES IN PSC POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners

More information

Petrescu Bogdan Mircea

Petrescu Bogdan Mircea Petrescu Bogdan Mircea Pregătire profesională 2000-2006, Universitatea de Medicină şi Farmacie "Carol Davila" Bucureşti, Facultatea Medicină Generală, Licenta 2006 2013 - Medic specialist psihiatru Funcții

More information

Hepatitis C Update on New Treatments

Hepatitis C Update on New Treatments Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts

More information

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic

More information

6 th UpDate. on Hepatology Course Bucharest Romania 2019 Title: From theory to practice in liver disease

6 th UpDate. on Hepatology Course Bucharest Romania 2019 Title: From theory to practice in liver disease 6 th UpDate on Hepatology Course Bucharest Romania 2019 Title: From theory to practice in liver disease COURSE DIRECTORS Liana GHEORGHE Anca TRIFAN Ioan SPOREA 5 th - 6 th April 2019 Bucharest Crowne Plaza

More information

The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy

The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy 280 POSITION PAPER : BELGIAN WORKING GROUP FOR HEPATITIS C The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy P. Stärkel 1, D. Vandijck 2,3, W. Laleman 4,

More information

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death

More information

Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients

Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients Editorial Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients Nobuhisa Akamatsu, Junichi Togashi, Kiyoshi Hasegawa, Norihiro Kokudo Artificial Organ and Transplantation

More information

Impatto della clearance virale e rischio di carcinoma epatocellulare

Impatto della clearance virale e rischio di carcinoma epatocellulare EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

The future of liver transplantation for viral hepatitis

The future of liver transplantation for viral hepatitis The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:

More information

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of

More information

ANDREI-DUMITRU MARGULESCU

ANDREI-DUMITRU MARGULESCU Curriculum vitae INFORMAŢII PERSONALE ANDREI-DUMITRU MARGULESCU Str. Maica Domnului 10, 023723 Bucuresti (Romania) 021 3180522 0726335271 andrei_marg@yahoo.com Sexul Masculin Data naşterii 27/06/1979 LOCUL

More information

Viral Hepatitis And Liver Transplantation

Viral Hepatitis And Liver Transplantation Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120

More information

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Editorial The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals Ming-Lung Yu 1,2,3, Chung-Feng

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C

More information

Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.

Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Review Med Ultrason 2014, Vol. 16, no. 2, 139-144 DOI: Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Mirela Dănilă, Ioan Sporea Gastroenterology

More information

Current Status of HBV and Liver Transplant

Current Status of HBV and Liver Transplant Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing

More information

ASSESSMENT AND MANAGEMENT OF POTENTIAL LIVER TRANSPLANT CANDIDATES

ASSESSMENT AND MANAGEMENT OF POTENTIAL LIVER TRANSPLANT CANDIDATES ASSESSMENT AND MANAGEMENT OF POTENTIAL LIVER TRANSPLANT CANDIDATES James YY Fung MBChB, MD, FRACP, FHKCP, FHKAM Consultant & Hon. Assoc. Professor Liver Transplant Center Department of Surgery, Queen Mary

More information

SCIENTIFIC PROGRAM Pharma Symposium Takeda: Changing the Game in IBD. Speakers: Bogdan Mateescu, Lucian Negreanu

SCIENTIFIC PROGRAM Pharma Symposium Takeda: Changing the Game in IBD. Speakers: Bogdan Mateescu, Lucian Negreanu SCIENTIFIC PROGRAM RCCC Annual Meeting 28 th -30 th of SEPEMBER 2017 Thursday 28 th of September 2017 ECCO educational workshop 17.30-18.30 Pharma Symposium Takeda: Changing the Game in IBD. Speakers:

More information

Spitalul Clinic Judetean de Urgenta str Clinicilor 3-5, , Cluj Napoca (Romania)

Spitalul Clinic Judetean de Urgenta str Clinicilor 3-5, , Cluj Napoca (Romania) Europass Curriculum Vitae Informatii personale Nume, Prenume (Nume anterior casatoriei: Padure ) Adresa Str. C.A.Rosetti, Nr. 16, Cluj Napoca (Romania) Telefon 0040745459080 E-mail(s) munteana2@yahoo.com

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

Dr. Cornelia NITIPIR. Curriculum vitae Europass. Informatii personale. Nume/Prenume: Adresa(e):... Telefon(oane):... Data nasterii: 16 iunie 1969

Dr. Cornelia NITIPIR. Curriculum vitae Europass. Informatii personale. Nume/Prenume: Adresa(e):... Telefon(oane):... Data nasterii: 16 iunie 1969 Curriculum vitae Europass Informatii personale Nume/Prenume: Dr. Cornelia NITIPIR Adresa(e):... Telefon(oane):... E-mail(uri): nitipir2003@yahoo.com Nationalitate (tati): Romaneasca Data nasterii: 16 iunie

More information

Outcome and Characteristics of Patients on the Liver Transplant Waiting List: Shiraz Experience

Outcome and Characteristics of Patients on the Liver Transplant Waiting List: Shiraz Experience 63 Original Article Outcome and Characteristics of Patients on the Liver Transplant Waiting List: Shiraz Experience F Khademolhosseini 1, SA Malekhosseini 2, H Salahi 2, S Nikeghbalian 2, A Bahador 2,

More information

Antiviral agents in HCV

Antiviral agents in HCV Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million

More information

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,

More information

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation

More information

Hepatology For The Nonhepatologist

Hepatology For The Nonhepatologist Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able

More information

White Nights of Hepatology 2016

White Nights of Hepatology 2016 White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding the cost

More information

a series of fact sheets written by experts in the field of liver disease HCV DISEASE PROGRESSION

a series of fact sheets written by experts in the field of liver disease HCV DISEASE PROGRESSION www.hcvadvocate.org HCSP FACT SHEET Foreword Over years or decades, chronic hepatitis C virus (HCV) infection can progress to severe liver problems including cirrhosis and hepatocellular carcinoma (HCC).

More information

The 10th National Symposium on Inflammatory Bowel Diseases

The 10th National Symposium on Inflammatory Bowel Diseases 1958 The 10 th National Symposium on Inflammatory Bowel Diseases Crowne Plaza Hotel, Bucharest, 27 th - 29 th of September 2018 The First Franco- Romanian Meeting Program www.rccc-congress.ro office.rccc@gmail.com

More information

PEDIATRIC LIVER TRANSPLANTATION: INDICATIONS AND TECHNICAL PROCEDURES

PEDIATRIC LIVER TRANSPLANTATION: INDICATIONS AND TECHNICAL PROCEDURES Annals of Academy of Romanian Scientists Online edition Series: Medical Sciences ISSN 2285-4150 Volume 1, Number 1/2010 41 PEDIATRIC LIVER TRANSPLANTATION: INDICATIONS AND TECHNICAL PROCEDURES Irinel POPESCU

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt

More information

Accepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?

Accepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Accepted Manuscript Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Qing-Lei Zeng, Zhi-Qin Li, Hong-Xia Liang, Guang-Hua Xu, Chun-Xia

More information

Liver disease in 2017: challenges and opportunities

Liver disease in 2017: challenges and opportunities Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National

More information

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Hepatocellular Carcinoma: Can We Slow the Rising Incidence? Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline

More information

HCV care after cure. This program is supported by educational grants from

HCV care after cure. This program is supported by educational grants from HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico

More information

Liver transplantation for HCV and HBV in The Czech Republic. Soňa Fraňková Institute for Clinical and Experimental Medicine Prague, Czech Republic

Liver transplantation for HCV and HBV in The Czech Republic. Soňa Fraňková Institute for Clinical and Experimental Medicine Prague, Czech Republic Liver transplantation for HCV and HBV in The Czech Republic Soňa Fraňková Institute for Clinical and Experimental Medicine Prague, Czech Republic Disclosures Speaking fees: Abbvie, Gilead, MSD, Novartis

More information

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008 Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Abstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.

Abstract and Introduction. Patients and Methods.   M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S. www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;

More information

9th Paris Hepatitis Conference

9th Paris Hepatitis Conference 9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units

More information

Transient elastography in chronic viral liver diseases

Transient elastography in chronic viral liver diseases 4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique

More information

Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York

Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:

More information

Prognostic Significance of CD44 Expression in Hepatocellular Carcinoma Following a Potentially Curative Treatment

Prognostic Significance of CD44 Expression in Hepatocellular Carcinoma Following a Potentially Curative Treatment ORIGINAL PAPER J. Transl. Med. Res 2016;21(4):267-273 DOI: 10.21614/jtmr-21-4-101 Prognostic Significance of CD44 Expression in Hepatocellular Carcinoma Following a Potentially Curative Treatment Razvan

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

Nume / Prenume Negreanu Lucian Conferentiar Universitar Medician Interna si Gastroenterologie, Abilitat

Nume / Prenume Negreanu Lucian Conferentiar Universitar Medician Interna si Gastroenterologie, Abilitat Curriculum vitae Europass Informaţii personale Nume / Prenume Negreanu Lucian Conferentiar Universitar Medician Interna si Gastroenterologie, Abilitat Adresă(e) Spitalul UnivBucuresti, splaiul independentei

More information

Treatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Treatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation

More information

Treatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble

Treatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989

More information

Doina-Andrada MIHAI CURRICULUM VITAE. Informaţii personale Data şi locul naşterii Nume purtat anterior căsătoriei Adresă , Bucureşti Bojin

Doina-Andrada MIHAI CURRICULUM VITAE. Informaţii personale Data şi locul naşterii Nume purtat anterior căsătoriei Adresă , Bucureşti Bojin CURRICULUM VITAE Doina-Andrada MIHAI Informaţii personale Data şi locul naşterii Nume purtat anterior căsătoriei Adresă E-mail 09.05.1974, Bucureşti Bojin Institutul Național de Diabet, Nutriţie şi Boli

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

Hepatitis C Management and Treatment

Hepatitis C Management and Treatment Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause

More information

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment

More information

Cancer Mortality in Romania, Digestive Sites: Esophagus, Stomach, Colon and Rectum, Pancreas, Liver, Gallbladder and Biliary Tree

Cancer Mortality in Romania, Digestive Sites: Esophagus, Stomach, Colon and Rectum, Pancreas, Liver, Gallbladder and Biliary Tree ORIGINAL PAPER Cancer Mortality in Romania, 1955-2004. Digestive Sites: Esophagus, Stomach, Colon and Rectum, Pancreas, Liver, Gallbladder and Biliary Tree Simona Vălean 1, Petru Armean 2, Simona Resteman

More information

HCC: Is it an oncological disease? - No

HCC: Is it an oncological disease? - No June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -

More information

Hepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM

Hepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

More information

RELEVANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN ) IN EVALUATION OF HEPATIC B VIRUS CHRONICALLY INFECTED PATIENTS

RELEVANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN ) IN EVALUATION OF HEPATIC B VIRUS CHRONICALLY INFECTED PATIENTS ORIGINAL ARTICLES RELEVANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN ) IN EVALUATION OF HEPATIC B VIRUS CHRONICALLY INFECTED PATIENTS Diana Nicolita, Ioan Sporea, Roxana Sirli, Alexandra Deleanu, Adriana Tudora,

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi

More information

THE EFFICACY OF THE PEGINTERFERON TREATMENT IN CHRONIC HEPATITIS HDV AND COMPENSATE LIVER CIRRHOSIS

THE EFFICACY OF THE PEGINTERFERON TREATMENT IN CHRONIC HEPATITIS HDV AND COMPENSATE LIVER CIRRHOSIS Rev. Med. Chir. Soc. Med. Nat., Iaşi 2014 vol. 118, no. 2 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS THE EFFICACY OF THE PEGINTERFERON TREATMENT IN CHRONIC HEPATITIS HDV AND COMPENSATE LIVER CIRRHOSIS

More information

HEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation

HEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences

More information

Approved regimens for cirrhotic patients

Approved regimens for cirrhotic patients 5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis

More information

Barnes, Maisha. Habib, Adil. Kedia, Prashant

Barnes, Maisha. Habib, Adil. Kedia, Prashant Study Title PI Area of Discipline A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-

More information

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue

More information

ANTIVIRAL THERAPY FOR HCV. Alfredo Alberti

ANTIVIRAL THERAPY FOR HCV. Alfredo Alberti CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine

More information

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if: New HCV reimbursement criteria 01-2018 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ

More information

MedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article

MedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,

More information

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if:

New HCV reimbursement criteria Chronic hepatitis C regardless of fibrosis stage if: New HCV reimbursement criteria 01-2018 Chronic hepatitis C with F2 fibrosis stage Chronic hepatitis C regardless of fibrosis stage if: HIV-HCV coinfection HBV-HCV coinfection Listed for or post-solid organ

More information

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL

More information

Accepted Manuscript. Letter to the Editor. Reply to: From the CUPIC study: Great times are not coming (?)

Accepted Manuscript. Letter to the Editor. Reply to: From the CUPIC study: Great times are not coming (?) Accepted Manuscript Letter to the Editor Reply to: From the CUPIC study: Great times are not coming (?) Christophe Hezode, Helene Fontaine, Yoann Barthe, Fabrice Carrat, Jean-Pierre Bronowicki PII: S0-()00-

More information

ةي : لآا ةرقبلا ةروس

ةي : لآا ةرقبلا ةروس سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a

More information

RESULTS OF PEGINTERFERON ALFA-2A TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B IN THE WESTERN PART OF ROMANIA

RESULTS OF PEGINTERFERON ALFA-2A TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B IN THE WESTERN PART OF ROMANIA ORIGINAL ARTICLE RESULTS OF PEGINTERFERON ALFA-2A TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B IN THE WESTERN PART OF ROMANIA Roxana Șirli 1 *, Ioan Sporea 1, Milana Szilaski 1, Manuela Curescu 2, Mirela

More information

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal

More information

RJGE VOL.12, NR.2, JUNE 2003

RJGE VOL.12, NR.2, JUNE 2003 RJGE VOL.12, NR.2, JUNE 2003 ORIGINAL PAPER Correlation of sicam-1 and svcam-1 Level with Biochemical, Histological and Viral Findings in Chronic Hepatitis C after Interferon-a+ Ribavirin Therapy Corina

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty

More information